Gladstone Institutional Advisory LLC Purchases 13,587 Shares of Pfizer Inc. (NYSE:PFE)

Gladstone Institutional Advisory LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 164,432 shares of the biopharmaceutical company’s stock after buying an additional 13,587 shares during the period. Gladstone Institutional Advisory LLC’s holdings in Pfizer were worth $4,362,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of PFE. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the fourth quarter worth $26,000. Gladius Capital Management LP grew its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares in the last quarter. Teachers Insurance & Annuity Association of America bought a new position in shares of Pfizer in the 3rd quarter worth $35,000. Joseph Group Capital Management lifted its position in Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 771 shares during the last quarter. Finally, Sugar Maple Asset Management LLC purchased a new position in Pfizer in the 4th quarter worth $43,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the subject of several recent analyst reports. UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. Guggenheim reaffirmed a “buy” rating and set a $33.00 price target on shares of Pfizer in a report on Monday. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Performance

Pfizer stock opened at $25.53 on Wednesday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a 50 day simple moving average of $26.28 and a 200-day simple moving average of $27.69. The stock has a market cap of $144.69 billion, a price-to-earnings ratio of 18.11, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 earnings per share. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.74%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.